News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
261,933 Results
Type
Article (13954)
Company Profile (304)
Press Release (247675)
Section
Business (79395)
Career Advice (151)
Deals (13196)
Drug Delivery (34)
Drug Development (50335)
Employer Resources (31)
FDA (5685)
Job Trends (5117)
News (144190)
Policy (10022)
Tag
Academia (901)
Alliances (21533)
Alzheimer's disease (760)
Approvals (5668)
Artificial intelligence (70)
Bankruptcy (97)
Best Places to Work (4522)
Biotechnology (249)
Breast cancer (110)
Cancer (896)
Cardiovascular disease (71)
Career advice (132)
CAR-T (73)
Cell therapy (217)
Clinical research (40154)
Collaboration (311)
Compensation (129)
COVID-19 (1007)
C-suite (79)
Cystic fibrosis (67)
Data (986)
Diabetes (87)
Diagnostics (1210)
Drug discovery (57)
Earnings (29020)
Events (47219)
Executive appointments (249)
FDA (6058)
Funding (310)
Gene editing (63)
Gene therapy (163)
GLP-1 (311)
Government (1066)
Healthcare (6549)
Infectious disease (1045)
Inflammatory bowel disease (98)
IPO (7200)
Job creations (860)
Job search strategy (127)
Layoffs (188)
Legal (1375)
Lung cancer (131)
Lymphoma (62)
Manufacturing (87)
Medical device (2577)
Medtech (2578)
Mergers & acquisitions (6136)
Metabolic disorders (262)
Neuroscience (1006)
NextGen Class of 2024 (2004)
Non-profit (847)
Northern California (1096)
Obesity (142)
Opinion (91)
Parkinson's disease (78)
Patents (63)
People (25127)
Phase I (14159)
Phase II (18670)
Phase III (11821)
Pipeline (367)
Postmarket research (851)
Preclinical (5971)
Radiopharmaceuticals (205)
Rare diseases (204)
Real estate (1410)
Regulatory (8292)
Research institute (931)
Southern California (983)
Startups (1965)
United States (8717)
Vaccines (165)
Weight loss (84)
Date
Last 7 days (200)
Last 30 days (1366)
Last 365 days (20596)
2024 (20532)
2023 (22418)
2022 (26841)
2021 (27819)
2020 (23364)
2019 (16226)
2018 (11762)
2017 (13759)
2016 (11859)
2015 (14358)
2014 (10393)
2013 (7484)
2012 (7533)
2011 (7614)
2010 (7428)
Location
Africa (146)
Asia (16947)
Australia (2865)
California (2488)
Canada (817)
China (206)
Colorado (93)
Connecticut (104)
Europe (36476)
Florida (273)
Georgia (71)
Illinois (154)
Indiana (61)
Maryland (336)
Massachusetts (1961)
Michigan (58)
Minnesota (101)
New Jersey (635)
New York (692)
North Carolina (420)
Northern California (1096)
Ohio (82)
Pennsylvania (478)
South America (207)
Southern California (983)
Texas (282)
Washington State (249)
261,933 Results for "renova therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Beach
Renova Therapeutics Announces Potential Expansion of Gene Therapy Platform for Heart Failure, Diabetes and Related Conditions
Renova Therapeutics, a biotechnology company developing gene therapy-based treatments for cardiovascular and metabolic diseases, announced current and potential future clinical directions that can expand the use of its gene therapies to treat additional debilitating diseases.
June 12, 2024
·
4 min read
Biotech Beach
Renova Therapeutics Announces Strategic Focus and Roadmap Prioritization for Its Gene Therapies to Treat Heart Failure and Type 2 Diabetes Mellitus
Renova Therapeutics, a biotechnology company developing gene therapy-based treatments for cardiovascular and metabolic diseases, announced that it has focused its development and commercialization efforts for its RT-100 and RT-200 gene therapies on two primary regulatory pathways as key value drivers.
May 8, 2024
·
5 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
BlueWind Medical Reaches 100th Patient for the OASIS Study of the RENOVA™ iStim System
BlueWind Medical announces its 100th patient implant in their pivotal study for treating overactive bladder symptoms using an innovative medical device the RENOVA™ iStim.
July 6, 2021
·
3 min read
Press Releases
TNF Pharmaceuticals Announces Trial to Explore Effects of Lead Candidate in Sarcopenia/Frailty Induced by GLP-1 Weight Loss Drugs
December 20, 2024
·
7 min read
Genetown
Laborie Introduces the Next Generation RenovaRP Centesis System
Laborie Medical Technologies, Inc., a leading diagnostic and therapeutic medical technology company, is proud to announce the launch of the RenovaRP™ Centesis System, an innovative fluid drainage device designed to advance patient care and improve efficiency for healthcare professionals.
January 8, 2024
·
2 min read
Regulatory
FDA Warns Applied Therapeutics of ‘Objectionable Conditions’ in Govorestat Study
The agency’s warning letter outlines Applied Therapeutics’ failure to provide adequate information regarding the clinical trial—including a dosing error for govorestat—claims that the company said it had already addressed.
December 4, 2024
·
2 min read
·
Tristan Manalac
Press Releases
NeuroEM Therapeutics(R) Accepted into StartUp Health’s Alzheimer’s Moonshot Community(TM)
September 19, 2024
·
4 min read
Press Releases
Cara Therapeutics and Tvardi Therapeutics Announce Entry into Merger Agreement
December 18, 2024
·
16 min read
Complete response letters
Applied Therapeutics Crashes After FDA Rejection of Rare Disease Drug
After extending its review period to evaluate additional submissions, the FDA ultimately denied Applied Therapeutics’ govorestat for galactosemia, citing “deficiencies” with the application. The biotech plans to meet with the regulator to discuss the best way forward for the drug.
December 2, 2024
·
3 min read
·
Tristan Manalac
1 of 26,194
Next
